Cell
Volume 172, Issue 4, 8 February 2018, Pages 857-868.e15
Journal home page for Cell

Article
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

https://doi.org/10.1016/j.cell.2017.12.020Get rights and content
Under an Elsevier user license
open archive

Highlights

  • Wild-type KRAS expression affects cellular fitness in KRAS mutant LUAD

  • Wild-type KRAS expression impairs response to MEK inhibitors in KRAS mutant LUAD

  • Wild-type KRAS inhibitory effect is dependent on dimerization with mutant KRAS

  • Blocking mutant KRAS dimerization impairs oncogenic properties in vivo

Summary

The mechanism by which the wild-type KRAS allele imparts a growth inhibitory effect to oncogenic KRAS in various cancers, including lung adenocarcinoma (LUAD), is poorly understood. Here, using a genetically inducible model of KRAS loss of heterozygosity (LOH), we show that KRAS dimerization mediates wild-type KRAS-dependent fitness of human and murine KRAS mutant LUAD tumor cells and underlies resistance to MEK inhibition. These effects are abrogated when wild-type KRAS is replaced by KRASD154Q, a mutant that disrupts dimerization at the α4-α5 KRAS dimer interface without changing other fundamental biochemical properties of KRAS, both in vitro and in vivo. Moreover, dimerization has a critical role in the oncogenic activity of mutant KRAS. Our studies provide mechanistic and biological insights into the role of KRAS dimerization and highlight a role for disruption of dimerization as a therapeutic strategy for KRAS mutant cancers.

Keywords

KRAS oncogene
wild-type allele
dimerization
lung adenocarcinoma
MAPK pathway
MEK inhibitors
allelic imbalance
drug resistance

Cited by (0)

8

These authors contributed equally

9

Senior author

10

Lead Contact